Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan 25;2006(1):CD005138.
doi: 10.1002/14651858.CD005138.pub2.

Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration

U Reddy  1 , M Kryzstolik
Affiliations

Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration

U Reddy et al. Cochrane Database Syst Rev. .

Abstract

Background: Antiangiogenic therapy is a new approach to the treatment of neovascular age-related macular degeneration. Interferon alfa is one antiangiogenic agent thought to function by inhibiting the migration and proliferation of vascular endothelial cells. It has been used in the treatment of hepatitis, solid tumors and hematologic malignancies.

Objectives: The aim of this review was to investigate interferon alfa as a treatment modality for neovascular age-related macular degeneration.

Search strategy: We searched and identified trials from the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Group Trials Register, in The Cochrane Library (Issue 2, 2005), MEDLINE (1966 to 2005/06 week 1), EMBASE (1980 to 2005/week 23), LILACS (Latin American and Caribbean Health Science Literature Database) (June 2005) and the reference lists of included studies.

Selection criteria: This review included randomized controlled trials evaluating interferon alfa therapy in people with neovascular age-related macular degeneration who were followed for at least one year.

Data collection and analysis: Both review authors independently extracted data and assessed trial quality. No data synthesis was conducted as only one trial met the inclusion criteria.

Main results: The one included trial enrolled and randomized 481 participants from 45 centers worldwide into four groups. The study allowed for analysis of the number of participants who had lost three or more lines of vision at 52 weeks in three interferon alfa-2a groups versus placebo. The results show an odds ratio of 1.60 (95% Confidence Interval 1.01 to 2.53) indicating that interferon is associated with a 60% increased odds of losing three or more lines at 52 weeks. This finding is marginally statistical with a P value of 0.04 and indicates that the treatment has the potential for harm rather than benefit.

Authors' conclusions: At present there is not enough evidence to recommend the use of interferon alfa-2a for the treatment of age-related macular degeneration.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 INTEFERON ALFA‐2A (ALL DOSES) VERSUS PLACEBO, Outcome 1 Visual acuity: loss of at least 3 lines of vision at 52 weeks.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD005138

References

References to studies included in this review

PTMDSG 1997 {published data only}
    1. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa‐2a is ineffective for patients with choroidal neovascularization secondary to age‐related macular degeneration. Results of a prospective randomized placebo‐controlled clinical trial. Archives of Ophthalmology 1997;115(7):865‐72. - PubMed

References to studies excluded from this review

Engler 1994 {published data only}
    1. Engler C, Sander B, Villumsen J, Lund‐Andersen H. Interferon alfa‐2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation. BJO 1994;78(10):749‐53. - PMC - PubMed
Poliner 1993 {published data only}
    1. Poliner LS, Tornambe PE, Michelson PE, Heitzmann JG. Interferon alpha‐2a for subfoveal neovascularization in age‐related macular degeneration. Ophthalmology 1993;100:1417‐24. - PubMed

Additional references

Aiello 1994
    1. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994;331(22):1480‐7. - PubMed
AREDS 2000
    1. Age‐Related Eye Disease Study Research Group. Risk factors associated with age‐related macular degeneration. A case‐control study in the age‐related eye disease study: age‐related eye disease study report number 3. Ophthalmology 2000;107(12):2224‐32. - PMC - PubMed
AREDS 2001
    1. Age‐Related Eye Disease Study Research Group. A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology 2001;119(10):1414‐36. - PMC - PubMed
Baron 1991
    1. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266(10):1375‐83. - PubMed
Brouty‐Boye 1980
    1. Brouty‐Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208(4443):516‐8. - PubMed
Evans 1995
    1. Evans JR. Causes of blindness and partial sight in England and Wales 1990‐91. Studies on Medical and Population Subjects no 57. London: HMSO, 1995.
Friedman 2004
    1. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, Jong PT, et al. Prevalence of age‐related macular degeneration in the United States. Archives of Ophthalmology 2004;122(4):564‐72. - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Assessing study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Klein 2002
    1. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten‐year incidence and progression of age‐related maculopathy: The Beaver Dam eye study. Ophthalmology 2002;109(10):1767‐79. - PubMed
Kvanta 1996
    1. Kvanta A Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age‐related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology & Visual Science 1996;37(9):1929‐34. - PubMed
Leibowitz 1980
    1. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973‐1975. Survey of Ophthalmology 1980;24 (Suppl):335‐610. - PubMed
Lopez 1996
    1. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age‐related macular degeneration‐related choroidal neovascular membranes. Investigative Ophthalmology & Visual Science 1996;37(5):855‐68. - PubMed
Miller 1993
    1. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha‐interferon. Ophthalmology 1993;100(1):9‐14. - PubMed
Mitchell 2002
    1. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5‐year incidence of age‐related maculopathy: the Blue Mountains Eye Study. Archives Ophthalmology 2002;120(10):1357‐63. - PubMed
MPSG 1991
    1. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy Five‐year results from randomized clinical trials. Archives of Ophthalmology 1991;109(8):1109‐14. - PubMed
Piguet 1993
    1. Piguet B, Wells JA, Palmvang IB, Wormald R, Chisholm IH, Bird AC. Age‐related Bruch's membrane change: a clinical study of the relative role of heredity and environment. British Journal of Ophthalmology 1993;77(7):400‐3. - PMC - PubMed
Seddon 1997
    1. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age‐related maculopathy. American Journal of Ophthalmology 1997;123(2):199‐206. - PubMed
Silvestri 1994
    1. Silvestri G, Johnston PB, Hughes AE. Is genetic predisposition an important risk factor in age‐related macular degeneration?. Eye 1994;8(Pt 5):564‐8. - PubMed
TAP 1999
    1. Treatment of Age‐related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age‐related macular degeneration with verteporfin: one‐year results of 2 randomized clinical trials ‐TAP report. Archives of Ophthalmology 1999;117(10):1329‐45. - PubMed
Ting 2002
    1. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age‐related macular degeneration. Archives of Ophthalmology 2002;120(6):731‐7. - PubMed
Van Kerckhoven 2001
    1. Kerckhoven W, Lafaut B, Follens I, Laey JJ. Features of age‐related macular degeneration on optical coherence tomography. Bulletin de la Societe Belge d'Ophtalmologie 2001;281:75‐8. - PubMed
Vedula 2008
    1. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2] - DOI - PMC - PubMed
Wormald 2007
    1. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for nonvascular age‐related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [Art. No.: CD002030. DOI: 10.1002/14651858.CD002030.pub3] - PubMed

Publication types

LinkOut - more resources